Impact of fecal microbiome on the efficacy of neoadjuvant chemo-immunotherapy and colitis adverse events: Findings from the NADIM II TrialCANCER RESEARCHIF16.62024-03-220PRE
ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell Lung Cancer Cell Lines and Patient Plasma: Toward EV-Based Noninvasive TestingCLINICAL CHEMISTRYIF6.32022-03-285OA
KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitorESMO OPENIF8.32021-10-018OAAI
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatmentMOLECULAR ONCOLOGYIF4.52021-06-1816OAAI
ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinibTRANSLATIONAL LUNG CANCER RESEARCHIF3.52020-06-0117OAAI